Phase 4 N=18 Randomized Double-blind Basic Science

Salbutamol Use in Ozone Air Pollution by People With Asthma and/or Exercise Induced Bronchoconstriction (EIB)

Asthma and/or Exercise Induced Bronchoconstriction · Ozone Air Pollution

Bottom Line

View on ClinicalTrials.gov: NCT05087693 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Mar 2025

Primary outcome: Primary: Measured Before and 30 Minutes After Exercise in Each 1 Day Condition — 6.98; 5.96; -1.38; -.35 litres

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: Salbutamol (Drug); Placebo medication (Drug); Ozone (Other); Filtered Air (Other); Exercise (Other)
Age: Adult · 18+ yrs
Sex: All
Sponsor: University of British Columbia
Primary completion: Aug 2023

Outcome Measures

Outcome	Result	p-value
PRIMARY Measured Before and 30 Minutes After Exercise in Each 1 Day Condition	6.98; 5.96; -1.38; -.35	—
PRIMARY Change in FVC From Baseline to 30 Minutes After Exercise	.77; .39; -1.37; -1.44	—

Summary

Salbutamol use is increased in areas with high levels of ozone pollution and the potential consequences of this are not well known. The purpose of this study is to examine the effect of salbutamol on lung function and inflammation in people with asthma and/or EIB exercising in ozone air pollution. To examine this, we are planning a randomized cross over trial where people with asthma and/or EIB complete sub maximal exercise in four conditions on four separate days. The four condition are: ozone + salbutamol, filtered air + salbutamol, ozone + placebo medication, and filtered air + placebo medication.

Eligibility Criteria

Inclusion Criteria

Have asthma and/or EIB
Able to perform maximal exercise
Able to communicate sufficiently using the English language

Exclusion Criteria

Allergic to salbutamol (also known as Ventolin)
Pregnant or potentially pregnant
Have a history of smoking
Had an upper respiratory tract infection within the last 4 weeks
Have a chronic respiratory disease other than asthma or EIB

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05087693). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.